

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10554974	
	Filing Date		2006-03-02	
	First Named Inventor	Takagi		
	Art Unit	1614		
	Examiner Name	Kevin E. Weddington		
	Attorney Docket Number	DAISAN126511		

U.S.PATENTS							Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
/K.W./	1	5130333	A	1992-07-14	Pan			
/K.W./	2	5298497	A	1994-03-29	Tschollar			
/K.W./	3	6414126	B1	2002-07-02	Ellsworth			
If you wish to add additional U.S. Patent citation information please click the Add button.							Add	
U.S.PATENT APPLICATION PUBLICATIONS							Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button.							Add	
FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
/K.W./	1	0 671 170	EP	A1	1995-09-13	McGovern		<input type="checkbox"/>

/Kevin Weddington/

03/27/2010

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10554974
Filing Date		2006-03-02
First Named Inventor	Takagi	
Art Unit	1614	
Examiner Name	Kevin E. Weddington	
Attorney Docket Number	DAISAN126511	

/K.W./	2	0956867	EP	A1	1999-11-17	Liebel		<input type="checkbox"/>
/K.W./	3	9071540	JP	A	1997-03-08	Tsujita		<input type="checkbox"/>
/K.W./	4	95/13063	WO	A1	1995-05-18	Hirsch		<input type="checkbox"/>
/K.W./	5	00/45818	WO	A1	2000-08-10	Cameron		<input type="checkbox"/>
/K.W./	6	2004/052368	WO	A1	2004-06-24	Ohlsson		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
/K.W./	1	ARITA, Y., et al., "Adipocyte-Derived Plasma Protein Adiponectin Acts as a Platelet-Derived Growth Factor-BB-Binding Protein and Regulates Growth Factor-Induced Common Postreceptor Signal in Vascular Smooth Muscle Cell," Circulation 105:2893-2898, June 2002.	<input type="checkbox"/>
/K.W./	2	ARITA, Y., et al., "Paradoxical Decrease of an Adipose-Specific Protein, Adiponectin, in Obesity," Biochemical and Biophysical Research Communications 257(1):79-83, April 1999	<input type="checkbox"/>
/K.W./	3	BALLANTYNE, C.M., et al., "Efficacy of Rosuvastatin 10 mg in Patients With the Metabolic Syndrome," American Journal of Cardiology 91(5A):25C-27C, March 2003.	<input type="checkbox"/>
/K.W./	4	BERG, A.H., et al., "The Adipocyte-Secreted Protein Acrp30 Enhances Hepatic Insulin Action," Nature Medicine 7(8):947-953, August 2001.	<input type="checkbox"/>

/Kevin Weddington/

03/27/2010

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10554974
Filing Date	2006-03-02
First Named Inventor	Takagi
Art Unit	1614
Examiner Name	Kevin E. Weddington
Attorney Docket Number	DAISAN126511

/K.W./	5	COMBS, T.P., et al., "Endogenous Glucose Production Is Inhibited by the Adipose-Derived Protein Acrp30," Journal of Clinical Investigation 108(12):1875–1881, December 2001.	<input type="checkbox"/>
	6	DEEDWANIA, P., and D. HUNNINGHAKE, "Comparative Effects of Statins on Atherogenic Dyslipidemia in Patients With the Metabolic Syndrome," Journal of the American College of Cardiology 43(5, Suppl A):485A, March 2004 (presented at the 53rd Annual Scientific Session of the American College of Cardiology, New Orleans, March 7–10, 2004) (Abstract 820-1).	<input type="checkbox"/>
	7	DROSSOS, T., et al., "Results of Pravastatin on Metabolic Parameters of Patients With Diabetes Mellitus Type II Under Simultaneous Treatment With Glybenclamide," Atherosclerosis 144:205, May 1999 (Abstract).	<input type="checkbox"/>
	8	HOTTA, K., et al., "Circulating Concentrations of the Adipocyte Protein Adiponectin Are Decreased in Parallel With Reduced Insulin Sensitivity During the Progression to Type 2 Diabetes in Rhesus Monkeys," Diabetes 50(5):1126–1133, May 2001.	<input type="checkbox"/>
	9	HUNNINGHAKE, D.B., et al., "Comparative Effects of Simvastatin and Atorvastatin in Hypercholesterolemic Patients With Characteristics of Metabolic Syndrome," Clinical Therapeutics 25(6):1670–1686, June 2003.	<input type="checkbox"/>
	10	INOUE, Y., et al., "A Multi-Centre Study of the Efficacy and Safety of Pravastatin in Hypercholesterolaemic Patients With Non-Insulin-Dependent Diabetes Mellitus," Current Medical Research and Opinion 13(4):187–194, 1994.	<input type="checkbox"/>
	11	KADOWAKI, T., and T. YAMAUCHI, "Adiponectin and Adiponectin Receptors," Endocrine Reviews 26(3):439–451, May 2005.	<input type="checkbox"/>
	12	KONDO, H., et al., "Association of Adiponectin Mutation With Type 2 Diabetes: A Candidate Gene for the Insulin Resistance Syndrome," Diabetes 51(7):2325–2328, July 2002.	<input type="checkbox"/>
	13	LINDSAY, R.S., et al., "Adiponectin and Development of Type 2 Diabetes in the Pima Indian Population," Lancet 360(9326):57–58, July 2002.	<input type="checkbox"/>
	14	MAEDA, K., et al., "cDNA Cloning and Expression of a Novel Adipose Specific Collagen-Like Factor, apM1 (Adipose Most Abundant Gene Transcript 1)," Biochemical and Biophysical Research Communications 221(2):286–289, 1996.	<input type="checkbox"/>
/K.W./	15	MAEDA, N., "PPAR $\gamma$ Ligands Increase Expression and Plasma Concentrations of Adiponectin, an Adipose-Derived Protein," Diabetes 50(9):2094–2099, September 2001.	<input type="checkbox"/>

/Kevin Weddington/

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10554974
Filing Date		2006-03-02
First Named Inventor	Takagi	
Art Unit	1614	
Examiner Name	Kevin E. Weddington	
Attorney Docket Number	DAISAN126511	

/K.W./	16	NEWMAN, C., et al., "Efficacy of Atorvastatin in Dyslipidemic Patients With Metabolic Syndrome in the ACCESS Study," Diabetes 52(Suppl 1):A494, 2003 (presented at the 63rd Scientific Sessions of the American Diabetes Association, New Orleans, June 13–17, 2003) (Abstract 2141-PO).	<input type="checkbox"/>
	17	OKAMOTO, Y., et al., "Adiponectin Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice," Circulation 106(22):2767–2770, November 2002.	<input type="checkbox"/>
	18	OLSSON, A.G., et al., "Rosuvastatin: A Highly Effective New HMG-CoA Reductase Inhibitor," Cardiovascular Drug Reviews 20(4):303–328, January 2002.	<input type="checkbox"/>
	19	ORSI, A., et al., "Simvastatin-Associated Memory Loss," Pharmacotherapy 21(6):767–769, June 2001.	<input type="checkbox"/>
	20	OUCHI, N., et al., "Adipocyte-Derived Plasma Protein, Adiponectin, Suppresses Lipid Accumulation and Class A Scavenger Receptor Expression in Human Monocyte-Derived Macrophages," Circulation 103(8):1057–1063, February 2001.	<input type="checkbox"/>
	21	OUCHI N., et al., "Adiponectin, an Adipocyte-Derived Plasma Protein, Inhibits Endothelial NF-κB Signaling Through a cAMP-Dependent Pathway," Circulation 102(11):1296–1301, September 2000.	<input type="checkbox"/>
	22	OUCHI, N., "Novel Modulator for Endothelial Adhesion Molecules: Adipocyte-Derived Plasma Protein Adiponectin," Circulation 100(25):2473–2476, December 1999.	<input type="checkbox"/>
	23	PANIAGUA, J.A., et al., "Cerivastatin Improves Insulin Sensitivity and Insulin Secretion in Early-State Obese Type 2 Diabetes," Diabetes 51(8):2596–2603, August 2002.	<input type="checkbox"/>
	24	REAVEN, G.M., "Banting Lecture 1988: Role of Insulin Resistance in Human Disease," Diabetes 37(12):1595–1607, December 1988.	<input type="checkbox"/>
	25	ROSS, R., "The Pathogenesis of Atherosclerosis: A Perspective for the 1990s," Nature 362(6423):801–809, April 1993.	<input type="checkbox"/>
/K.W./	26	SAITO, Y., et al., "Statin Reverses Reduction of Adiponectin Receptor Expression in Infarcted Heart and in TNF-α-Treated Cardiomyocytes in Association With Improved Glucose Uptake," American Journal of Physiological: Heart and Circulatory Physiology 293(6):H3490–H3497, December 2007.	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10554974
Filing Date	2006-03-02
First Named Inventor	Takagi
Art Unit	1614
Examiner Name	Kevin E. Weddington
Attorney Docket Number	DAISAN126511

/K.W./	27	SCHULZE, M.B., et al., "Adiponectin and Future Coronary Heart Disease Events Among Men With Type 2 Diabetes," Diabetes 54(2):534-539, February 2005.	<input type="checkbox"/>
	28	SUGIMOTO, T., "Pravastatin Versus Simvastatin in Hyperlipidemic Patients With Type 2 Diabetes Mellitus," Current Therapeutic Research 60(7):404-413, July 1999.	<input type="checkbox"/>
	29	WEYER, C., et al., "Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association With Insulin Resistance and Hyperinsulinemia," Journal of Clinical Endocrinology & Metabolism 86(5):1930-1935, May 2001.	<input type="checkbox"/>
	30	YAMAUCHI, T., et al., "The Fat-Derived Hormone Adiponectin Reverses Insulin Resistance Associated With Both Lipoatrophy and Obesity," Nature Medicine 7(8):941-946, August 2001.	<input type="checkbox"/>
	31	YOKOTA, T., et al., "Adiponectin, a New Member of the Family of Soluble Defense Collagens, Negatively Regulates the Growth of Myelomonocytic Progenitors and the Functions of Macrophages," Blood 96(5):1723-1732, September 2000.	<input type="checkbox"/>
	32	ZOCCALI, C., et al., "Adiponectin, Metabolic Risk Factors, and Cardiovascular Events Among Patients With End-Stage Renal Disease," Journal of the American Society of Nephrology 13(1):134-141, January 2002.	<input type="checkbox"/>
/K.W./	33	Supplementary European Search Report dated July 14, 2009, issued in corresponding European Application No. EP 04 72 9730, filed April 27, 2004.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button **Add**

**EXAMINER SIGNATURE**

Examiner Signature	/Kevin Weddington/	Date Considered	03/27/2010
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.